INSM · Insmed
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Note written ·
The last three months
Up 14.0% since the close; the S&P 500 is down 9.4% over the same sessions. Figures in the note can cover a different window.
Daily closes, to . Red: the note's price line under the older rule, a daily close below $119.80, set on 20 November 2026. The pale line is the 50-day average, $111.09 on .
Price line
A daily close below $119.80, the 18 November 2026 close before the Sanofi report, which would show the takeover premium gone. An FDA rejection of the Arikayce label expansion on 28 January 2027 would also show the case failing.
A price line, set under the rules before kill lines became business results on 20 November 2026. It stays until the note's next read replaces it; a close through it only makes the note due for a fresh read.
Research onlyNot in the portfolio.
The business · as of
Insmed sells two drugs for serious lung diseases. Brinsupri treats non-cystic fibrosis bronchiectasis. Arikayce treats MAC lung infection. Both are sold in the US, Europe and Japan. Revenue was $524.4 million in the quarter to 30 September 2026, of which Brinsupri brought in $400.1 million.
What is changing, and what follows · as of
- What is changing now
- On 19 November 2026 Bloomberg reported that Sanofi is weighing a takeover of Insmed and speaking with advisers. The shares closed at $144.46, up from $119.80 the session before.
- What follows for the company
- Brinsupri sales lifted gross margin to 85.1% and cut the operating loss to $89.4 million in the third quarter of 2026. Research spending of $270.0 million still kept four-quarter free cash flow at −$628 million.
- What follows for its customers, suppliers and competitors
- A bid would give Sanofi (SNY) a respiratory drug launch as Dupixent patents near expiry, and Bloomberg said other suitors could emerge. TPIP targets markets United Therapeutics (UTHR) serves with Tyvaso.
What the price assumes · as of
At the 19 November 2026 close (filed inputs to 29 October 2026) the shares trade at 20.5 times sales and 43.6 times book value, for an enterprise value of $31,092 million. EV/EBIT and P/E are not meaningful because the company still loses money. That holds only if revenue keeps compounding from the latest quarter's $524 million while the −17.0% operating margin turns positive.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 29 October 2026; valuation at the 20 November 2026 close
The last six quarters
- Revenue, latest quarter ($M)
- 524
- Revenue, change on a year (%)
- +268.4
- Gross margin (%)
- 85.1
- Operating margin (%)
- −17.0
- Free cash flow, four quarters ($M)
- −628
- Net cash, cash less debt ($M)
- 600
- Enterprise value to sales (×)
- 20.0
- Free-cash-flow yield (%)
- −2.0
All filed numbers
What Insmed reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 524 | +268.4 | 85.1 | −17.0 |
| first filed | 426 | +296.1 | 84.2 | −0.4 |
| first filed | 306 | +229.6 | 84.5 | −50.1 |
| first filed | 264 | +152.6 | 83.2 | −121.2 |
| first filed | 142 | +52.4 | 79.4 | −257.1 |
| first filed | 107 | +18.9 | 73.9 | −291.3 |
| Pre-tax income ($M) | −97.7 |
|---|---|
| Net income ($M) four quarters: −606 | −100 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +3.3 |
| Operating cash flow ($M) | −596 |
|---|---|
| Capital spending ($M) | 32.0 |
| Free cash flow ($M) | −628 |
| Cash and short-term investments ($M) | 1,147 |
|---|---|
| Debt ($M) long-term debt | 547 |
| Net cash, cash less debt ($M) | 600 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 259 |
| Inventory ($M) | 164 |
| Shareholders' equity ($M) | 726 |
| Market value ($M) | 31,005 |
|---|---|
| Enterprise value, market value plus net debt ($M) | 30,405 |
| Enterprise value to sales (×) | 20.0 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 42.7 |
| Free-cash-flow yield (%) | −2.0 |
Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 6.4% of shares outstanding sold short, 3.6 days of average trading to cover, +4.5% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 days | Not available yet | Not available yet |
| 12 months | Not available yet | Not available yet |
Linked companies · as of
- Competitors:
- UTHR
The thesis
Insmed's shares are more likely than not to beat the S&P 500 over the next three months. Two things support that view. Bloomberg reported on 19 November 2026 that Sanofi is weighing a takeover. Separately, the company's lung-disease drug Brinsupri sold $400.1 million in its third full quarter on the market. The Food and Drug Administration (FDA) decision on the Arikayce label expansion, due 28 January 2027, is the next dated test. Whether Sanofi makes a bid is the other.
The rating is Medium. The takeover report puts a floor of interest under the shares, and the launch numbers give a buyer a reason to pay. It is not High because no offer exists. Reuters reported on 19 November 2026 that neither company commented and that any deal "could still be weeks away." Without a bid, the gain from the report can unwind.
Bullish and bearish views on Insmed Incorporated
The bull case on Insmed Incorporated (INSM), in brief: Brinsupri launch is ahead of plan. The bear case: the premium rests on an unconfirmed report.
Bull case
- Brinsupri launch is ahead of plan. Brinsupri revenue was $400.1 million in the quarter to 30 September 2026, up 29% from $309.2 million in the previous quarter. Total revenue was $524.4 million, up 268% from a year earlier (company 8-K, 29 October 2026).
- Guidance floor moved up. On 29 October 2026 the company raised the low end of its 2026 Brinsupri revenue guidance to $1.35–1.4 billion, from $1.25–1.4 billion. It raised Arikayce guidance to $460–470 million, from $450–470 million.
- A strategic buyer is circling. Bloomberg reported on 19 November 2026 that Sanofi is speaking with advisers about a takeover. The same report said other suitors could emerge. Sanofi's chief executive has called business development "critical" ahead of Dupixent patent expiries in the early 2030s.
- Margins are moving the right way. Gross margin rose to 85.1% in the quarter to 30 September 2026, from 79.4% a year earlier. The operating margin improved to −17.0%, from −257.1% (10-Q filed 29 October 2026).
- A near-term regulatory event. The FDA accepted the Arikayce supplemental application for all patients with MAC lung disease under Priority Review. The decision date is 28 January 2027 (company 8-K, 29 October 2026). MAC is Mycobacterium avium complex, a hard-to-treat lung infection.
Bear case
- The premium rests on an unconfirmed report. The 19 November 2026 move came from a Bloomberg report citing people familiar with the matter. Neither company commented to Reuters that day. If Sanofi steps back, the report-day gain could unwind.
- Still losing money and burning cash. The net loss was $100.3 million in the quarter to 30 September 2026. Free cash flow was −$628 million over the four quarters to that date. Cash and short-term investments were $1,147 million against $547 million of long-term debt (10-Q filed 29 October 2026).
- Heavy spending on the next drug. Research and development expense rose to $270.0 million in the third quarter of 2026, from $186.4 million a year earlier. The pipeline includes three TPIP Phase 3 programs. PALM-ILD enrollment is not expected to finish until the first half of 2028 (company 8-K, 29 October 2026).
- Earnings missed the consensus. The third-quarter 2026 loss of $0.46 a share was wider than the Zacks consensus loss of $0.34 (Zacks, 29 October 2026).
- A director sold before the rally. Director David R. Brennan sold 25,000 shares in the open market at $124.00 on 9 September 2026 (SEC Form 4, filed 11 September 2026).
Price setup · as of
The shares closed at $144.46 on 19 November 2026, up from $119.80 on 18 November 2026, on the day of the Sanofi report. The price had held between $118.07 and $122.88 from 12 November to 18 November 2026. The 19 November 2026 close is above the 50-day moving average of $110.86 and the 200-day moving average of $122.61, both as of that close.
The 3-month price change is 14.9%, against a reference close of $125.77 on 21 August 2026. The shares are still 32.1% below the 52-week intraday high of $212.75, set on 2 December 2025. The 52-week closing low was $91.88 on 10 June 2026. The pre-report closes from $118 to $123 mark where the price traded before takeover interest became public. A return to that range would mean the market no longer expects a bid.
Across liquid US stocks, no reliable effect has been found so far for what a one-day jump of this size means for the following 21 or 63 sessions.
Catalysts ahead
- 28 January 2027: FDA decision date on the Arikayce supplemental application for all MAC lung disease patients. Approval would widen Arikayce's US market and support the case. A rejection would weaken both the drug's growth and a buyer's valuation.
- ~19 February 2027 (est.): Fourth-quarter and full-year 2026 results. Shows whether full-year Brinsupri revenue lands within the $1.35–1.4 billion guidance, and whether the operating loss keeps narrowing.
What would change the view
The risks this note tracks, each with what would confirm it:
- Sanofi decides not to bid and the takeover premium leaves the shares. Confirmed by: a statement from Sanofi or Insmed, or a follow-up report from Bloomberg or Reuters, saying talks have ended or that no approach is under way.
- Brinsupri growth slows as the launch matures. Confirmed by: fourth-quarter 2026 Brinsupri revenue that puts the full year below the $1.35 billion low end of guidance.
- The FDA does not approve the wider Arikayce label. Confirmed by: a complete response letter, or a delay announced on or before the 28 January 2027 decision date.
- Cash burn forces new share sales, diluting holders. Confirmed by: an equity or convertible offering. Diluted shares were already up 3.3% from a year earlier in the quarter to 30 September 2026.
What it trades with · as of
For now the shares are trading on the deal. Their next big move depends on news from Sanofi (SNY), or a denial, more than on the biotech group. Brinsupri sales and the FDA decision on 28 January 2027 drive the company-specific path.
TPIP, Insmed's inhaled treprostinil, is aimed at markets United Therapeutics (UTHR) serves with Tyvaso. Trial news in pulmonary hypertension moves both names. Single stocks vary widely: the standard deviation of 63-session returns across liquid US stocks was 27% in 2026, so a three-month result for one name is a noisy reading.
Caveats
- Insmed is not yet profitable: its net loss was $100.3 million in the quarter to 30 September 2026, and free cash flow was negative over the four quarters to that date. Form 10-Q for the third quarter of 2026 · as of
The evidence, claim by claim (8)
- Third-quarter 2026 revenue was $524.4 million, up 268% from $142.3 million a year earlier. Brinsupri contributed $400.1 million and Arikayce $124.4 million. Insmed 8-K, exhibit 99.1, 29 October 2026 · as of
- Insmed raised its 2026 Brinsupri revenue guidance to $1.35–1.4 billion, from $1.25–1.4 billion. It raised Arikayce guidance to $460–470 million, from $450–470 million. Insmed 8-K, exhibit 99.1, 29 October 2026 · as of
- The FDA accepted the Arikayce supplemental application for all MAC lung disease patients under Priority Review, with a decision date of 28 January 2027. Insmed 8-K, exhibit 99.1, 29 October 2026 · as of
- Bloomberg reported that Sanofi is weighing a takeover of Insmed and speaking with advisers. Neither company immediately commented to Reuters. Reuters via Yahoo News, 19 November 2026 · as of
- The third-quarter 2026 net loss was $100.3 million, or $0.46 a share. The Zacks consensus loss was $0.34 a share. Zacks, 29 October 2026; Insmed 8-K, 29 October 2026 · as of
- Cash and short-term investments were $1,147 million against $547 million of long-term debt at 30 September 2026. Insmed 10-Q for the third quarter of 2026 · as of
- Director David R. Brennan sold 25,000 shares in the open market at $124.00 on 9 September 2026. SEC Form 4 filed 11 September 2026 · as of
- Brinsupri was approved in Japan in August 2026 for non-cystic fibrosis bronchiectasis and launched there in October 2026. Insmed 8-K, exhibit 99.1, 29 October 2026 · as of
Sources
- INSMED Inc - Form 8-K - FY2026 · sec.gov ·
- Sanofi weighs takeover of US drugmaker Insmed, Bloomberg News reports · malaysia.news.yahoo.com ·
- Sanofi Considers Buying Insmed as Pharma Giants Seek New Drug Portfolios · bloomberg.com ·
- INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance · zacks.com
Related · shared themes
MOD
Modexus Solutions
Modexus Solutions (formerly Modine Manufacturing) is modestly more likely to beat the S&P 500 over three months, as a reported Samsung bid…
ADT
ADT
ADT Inc. trades as a pending $10.00-per-share cash buyout by Thrive Holdings, so its shares are more likely to lag the S&P 500 than lead…
AES
AES
AES Corporation is more likely to lag the S&P 500 over three months because its shares are fixed to a $15.00 cash takeover by a GIP- and…
AMBA
Ambarella
Ambarella's shares are more likely to lag the S&P 500 over three months: they sit below their 50-day and 200-day averages and the reported…